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Transforming growth factor-b2 (TGF-b2) is an impor-
tant regulator of cell proliferation and differentiation;
however, its transcriptional regulation is not well un-
derstood. Here we report characterization of an essen-
tial E-box motif, positioned at 250/245 between a previ-
ously described functional cAMP response element/
activating transcription factor site and the TATA box of
the human TGF-b2 promoter. By site-directed mutagen-
esis, we demonstrate that this E-box motif is necessary
for the promoter activity, not only in differentiated cells
derived from embryonal carcinoma cells, but also in
choriocarcinoma cells and in MCF-7 breast carcinoma
cells. We also demonstrate that the transcription factors
USF1 and USF2 bind to this E-box motif in vitro when
nuclear extracts from each of these cell lines are exam-
ined by gel retardation assays. Moreover, using a domi-
nant-negative USF2 protein, we show that USF proteins
are critical for TGF-b2 promoter activity in vivo. The
importance of the E-box motif described in this study is
supported by the presence of an E-box motif in the same
position in the chicken TGF-b2 gene promoter.
Transforming growth factor-b2 (TGF-b2),1 like other growth
factors in the TGF-b family, is involved in the regulation of
many different cellular functions, including cell proliferation
and differentiation as well as production and maintenance of
extracellular matrices (reviewed in Refs. 1 and 2). Through its
multifaceted effects, TGF-b2 plays important regulatory roles
in a host of biological events, from embryogenesis through
repair processes, to regulation of the immune system. Hence,
the regulation of TGF-b2 gene in various systems warrants
detailed investigation. The studies presented here focus on the
transcriptional regulation of the TGF-b2 gene in embryonal
carcinoma (EC) cells and their differentiated counterparts,
which represent a model system of early embryonic develop-
ment (reviewed in Ref. 3). Given the importance of TGF-b2
production in implantation and in tumor malignancy (4–6), we
extended our studies to two choriocarcinoma cell lines and a
breast carcinoma cell line. Previous work demonstrated the
presence of a critical positive regulatory region in the TGF-b2
gene promoter, localized between 277 and 163, where 11 is
the transcription start site (7–9). This region contains a func-
tional CRE/ATF motif, which is indispensable for the positive
effect of this promoter region in different cell types and capable
of binding activating transcription factor 1 (ATF-1) in vitro.
Recently, computerized sequence analysis demonstrated that
the human TGF-b2 promoter also contains a CACGTG motif
between 250 and 245, which conforms to the consensus se-
quence of an E-box motif, CANNTG (10). Interestingly, this
E-box motif appears to be evolutionarily conserved, since the
same CACGTG sequence is present in the chicken TGF-b2
promoter, and it is located in the same position relative to the
similarly conserved CRE/ATF site and the TATA box of the
chicken promoter (11). Thus, the putative E-box motif localizes
to the previously identified positive regulatory region, which
has been shown to be inactive in undifferentiated EC cells, but
becomes active when EC cells are induced to differentiate, and,
consequently, express TGF-b2 both at the RNA and protein
levels. E-box motifs in other gene promoters have been shown
to bind members of the bHLH-LZ family of transcription fac-
tors, including c-myc (12), Max (13), USF (14), or TFE3 (15)
proteins, where the flanking nucleotides of the motif appear to
provide for the discrimination in binding between different
family members (16). Some of these transcription factors can
act as either transactivators or repressors of gene expression,
depending on the gene promoter or on their dimerization part-
ner (17–21). Therefore, we examined whether the putative
E-box motif in the TGF-b2 gene promoter is involved in nega-
tive and/or positive regulation of the gene in several cell types.
Our results demonstrate that the 250/245 E-box motif is crit-
ical for the positive effect of the 277/163 regulatory region of
the TGF-b2 gene promoter in differentiated cells derived from
both murine and human EC cells. We also demonstrate that
the transcription factors USF1 and USF2 are able to bind to
this site in vitro before and after differentiation of EC cells.
Importantly, similar observations were made in JAR and
JEG-3 choriocarcinoma cells and MCF-7 breast cancer cells.
Finally, a dominant-negative USF2-expression vector was used
to demonstrate that USF transcription factors are utilized as
positive transactivators of the TGF-b2 gene in differentiated
cells derived from EC cells.
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EXPERIMENTAL PROCEDURES
Dulbecco’s modified Eagle’s medium was obtained from Life Tech-
nologies, Inc., and fetal bovine serum was obtained from HyClone
(Logan, UT). All-trans-retinoic acid was purchased from Eastman
Kodak Co. All other chemicals were purchased from Sigma, unless
otherwise indicated.
Cell Culture and Differentiation of EC Cells—All cell lines were
maintained and induced to differentiate as described previously, unless
indicated otherwise (1, 8, 22, 23).
Preparation of Cell Extracts and Gel Mobility Shift Assay—Nuclear
extracts were prepared as described previously (24) with slight modifi-
cations of the original method of Dignam et al. (25). Nuclear extracts
were prepared in the presence of the protease inhibitors: pepstatin A,
antipain, chymostatin, leupeptin (1 mg/ml), phenylmethylsulfonyl fluo-
ride (1 mM), soybean trypsin inhibitor (20 mg/ml), benzamidine (2.5 mM),
aprotinin (2.5 KIU/ml). Nuclear extracts of F9 EC cells and F9-
differentiated cells also contained protein phosphatase inhibitors:
(NH4)2MoO4 (1 mM) and NaF (5 mM). The dialysis buffer contained the
same protease inhibitors at a 10-fold lower final concentration. Protein
concentrations were determined using the Pierce Micro BCA Protein
Assay Reagent (Pierce). Gel mobility shift assays were based on the
method of Fried and Crothers (26). The protocol and reaction conditions
used in this report were the same as described previously (24), with the
exception that all binding reactions contained MgCl2 at a final concen-
tration of 3 mM. In addition, binding reactions with JAR, JEG-3, and
MCF-7 cell nuclear extracts were supplemented with 1.5 ml of 1 M NaCl
and 1 ml of 0.25 M NaH2PO4 per 20-ml reaction mixture to promote
binding of nuclear proteins. Reaction mixtures were incubated for 20
min at room temperature with F9 EC cell and F9-differentiated cell
nuclear extracts, and for 40 min at room temperature with JAR, JEG-3,
and MCF-7 cell nuclear extracts. The double-stranded oligodeoxynucle-
otide (dsODN) probes containing the wild type or mutant E-box motif
were as follows (the putative transcription factor binding site is under-
lined): wild type E-box probe: 59-ggcAGACACGTGGTT-39, and its com-
plement, 59-ctgAACCACGTGTCT-39; mutant E-box dsODN: 59-ggcA-
GACGAGTGGTT-39, and its complement, 59-ctgAACCACTCGTCT-39
(the mutations are double-underlined). When annealed, the probes had
59 overhangs (shown in lowercase), which permitted radioactive label-
ing by Klenow fill-in reaction. The nonspecific DNA competitor used in
the gel mobility shift assays was 0.05 mg/ml poly(dI)zpoly(dC) (Pharma-
cia Biotech Inc.). For supershift analyses, the binding reactions were
incubated overnight at 4 °C with the antibodies and the blocking pep-
tides indicated, prior to the addition of the labeled probe. The USF1-
and USF2-specific antibodies (catalog nos. sc-229 and sc-862, respec-
tively) and their respective blocking peptides were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Nondenaturing 4% poly-
acrylamide gels were run at 4 °C in high ionic strength buffer (50 mM
Tris base, 380 mM glycine, 2 mM EDTA).
Site-directed Mutagenesis of TGF-b2 Promoter/Reporter Gene Con-
structs—Site-directed mutagenesis of the 250/245 E-box motif (num-
bering is according to Noma et al. (27)) was carried out using a slight
modification of the PCR-based “megaprimer” method for mutagenesis,
using the same cycle conditions as described previously (23). Primers
for the first PCR were: Primer 1: 59- CGCGCGTTGGCCGATTCA-39,
and the mutagenic primer annealing to the E-box motif (the mutated
bases are in lower case): 59-TCTCTCTGAACCACtcGTCTGCCTTC-39.
Primers for the second PCR were: the “megaprimer,” which is the
product of the first PCR, and Primer 2: 59-GCCATTGGGATATAT-
CAACGGTGGTA-39. The mutant promoter fragment produced by the
second PCR was cloned into the pGEM4-SVOCAT plasmid digested
with PstI and KpnI. The entire promoter insert of the mutant clones
was sequenced to verify the presence of the desired point mutations in
the E-box motif, and to ensure that the Pfu polymerase did not intro-
duce additional point mutations during PCR.
Transient Transfection Assay—F9-differentiated cells (day 3), JAR
cells, and MCF-7 cells were transfected in monolayer by the calcium
phosphate precipitation method (28) as described previously (23, 24).
The normalization plasmid pCH110 (Pharmacia) contains the b-galac-
tosidase reporter gene under the control of the SV-40 promoter. In some
experiments (as indicated in the figure legends) the pCMVbg-normal-
izing plasmid was used, which contains the b-galactosidase reporter
gene under the control of the CMV promoter (CLONTECH, Palo Alto
CA). TGF-b2/CAT chimeric gene constructs were prepared as described
previously (8, 23). The eukaryotic expression plasmid producing a dom-
inant-negative USF2 protein was obtained from Dr. Miche´le Sawadogo
(University of Texas M.D. Anderson Cancer Center, Houston, TX) (29).
Plasmid DNA was purified by tip-500 columns (QIAGEN, Chatsworth,
CA).
RESULTS
An E-box Motif Is Critical for the TGF-b2 Promoter Activity
in Different Cell Lines—To determine the role of the 250/245
putative E-box motif in TGF-b2 promoter activity, we employed
site-directed mutagenesis to introduce point mutations in the
E-box motif in our promoter/reporter gene constructs. The wild
type E-box motif was changed to CGAGTG in the mutant
constructs, since mutations in the CACGTG core E-box se-
quence have been shown to significantly inhibit binding of
members of the bHLH-LZ family of transcription factors (30–
32). One of the constructs that was selected for mutagenesis,
pb2-77, contains the 277/163 fragment of the human TGF-b2
promoter. This region acts as a positive regulatory region of the
TGF-b2 promoter in all cell types studied (7–9). We also intro-
duced the same point mutations in the pb2-528 construct,
which contains 528 base pairs of the promoter region upstream
from the transcription start site. This allowed us to test the
function of the E-box in the context of a larger promoter region
(Fig. 1; the point mutations are in lowercase). To test the effects
of these changes, differentiated cells derived from the murine
EC cell line, F9, or the human EC cell line, NT2/D1, were
transiently transfected with the wild type or the mutant pro-
moter/reporter gene constructs (Fig. 2, A and B). Activity of the
pb2-40 construct served as the base line, since this construct
does not contain the E-box or the CRE/ATF site, and has a very
low basal activity in all cell lines studied (7, 8). The results
show clearly that mutations in the E-box motif significantly
reduce TGF-b2 promoter activity in both cell lines, not only in
the shorter construct, pb2-77E, but also in the context of a
larger promoter region, in the pb2-528E construct. Similar
results were obtained when the function of the E-box motif was
studied in JAR choriocarcinoma cells (Fig. 2C), MCF-7 breast
cancer cells (Fig. 2D), and JEG-3 choriocarcinoma cells (data
not shown). In NT2/D1-differentiated cells, mutation of the
E-box motif consistently resulted in slightly lower reduction of
promoter activity than what was observed with the mutated
CRE/ATF site, suggesting that cell-type specific differences
may exist in utilization of these cis-regulatory elements. Nev-
ertheless, the average reduction in promoter activity by the
E-box mutation was in a similar range (60–80%) to that ob-
served with mutations in the CRE/ATFmotif in both constructs
(9, 23), indicating that both cis-regulatory elements are func-
FIG. 1. Point mutations introduced in the E-box motif and
CRE/ATF site of the TGF-b2 promoter/reporter gene constructs.
The TGF-b2 promoter/reporter gene constructs were named pb2-n,
where “n” is the number of nucleotides upstream of the transcription
start site (8). pb2-528 (or “528”) contained the 2528/163 fragment of
the wild type human TGF-b2 promoter and the pb2-77 construct (or
“77”) contained the 277/163 fragment of the promoter. Mutant con-
structs 528M and 77M harbor point mutations in the CRE/ATF motif,
whereas mutant constructs 528E and 77E harbor point mutations in
the E-box motif (the mutations are in lowercase). 11, the transcription
start site.
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tional and critical for the activity of the TGF-b2 promoter in the
different cell types.
USF1 and USF2 Are Able to Bind to the TGF-b2 E-box
Motif—Gel mobility shift analysis was employed to identify the
transcription factors that bind to the TGF-b2 E-box motif in
vitro. First, E-box-binding activities in nuclear extracts of EC
cells and their differentiated counterparts were compared,
since the promoter is inactive in the undifferentiated cells, but
becomes active when the cells are induced to differentiate. F9
EC cell nuclear extracts formed one major and two minor
DNA-protein complexes with the wild type E-box dsODN probe
in the binding assays (Fig. 3, A and B). The minor complexes
can be observed more readily in Fig. 3B. The intensities of the
minor complexes varied between experiments and never ap-
proached the intensity of the major complex. F9-differentiated
cell nuclear extracts also formed one major DNA-protein com-
plex with the wild type E-box probe, plus a minor DNA-protein
complex (Fig. 3, A and B). Both DNA-protein complexes formed
with nuclear extracts of F9-differentiated cells co-migrated
with two of the complexes formed by F9 EC cell nuclear ex-
tracts (Fig. 3, A and B). These complexes bound specifically to
the E-box motif in the dsODN probe, since they were competed
effectively with a 25-fold molar excess of the same, unlabeled
dsODN containing the wild type E-box motif, but not with the
same excess of the mutant dsODN harboring two critical point
mutations in the E-box motif. Importantly, nuclear extracts
prepared from PYS-2 cells, NT2/D1 EC cells, or NT2/D1-differ-
entiated cells formed very similar DNA-protein complexes
when incubated with the wild type E-box probe, with the ex-
ception that the minor complex migrating just above the major
complex could be observed only with nuclear extracts prepared
from F9 EC cells (data not shown). PYS-2 cells were included in
this study, because these EC-derived differentiated cells also
express TGF-b2. Finally, no DNA-protein complexes formed
when nuclear extracts prepared from F9 EC cells or their
differentiated cells were incubated with the labeled mutant
dsODN as the probe (data not shown).
Interestingly, DNA binding by the major E-box binding pro-
tein was abolished by treatment with diamide, a commonly
used oxidizing agent, but was unaffected by boiling the nuclear
extracts for 10 min (data not shown). Since it has been shown
that of the E-box binding bHLH-LZ transcription factors, USF
proteins are both thermostable (33) and sensitive to oxidation
(34), we tested whether USF1- and USF2-specific polyclonal
antibodies could recognize the DNA-protein complexes formed
between nuclear extracts and the E-box probe. A USF2-specific
polyclonal antibody caused the formation of a supershifted
DNA-protein complex both in F9 EC cell and F9-differentiated
cell nuclear extracts (Fig. 3A). On the other hand, addition of
USF1-specific antibody to the binding reaction resulted in the
formation of two supershifted complexes both in F9 EC and
F9-differentiated cell nuclear extracts (Fig. 3B). Neither anti-
bodies recognized the minor DNA-protein complexes, since no
change in their migration or intensities was observed. Al-
though the supershift of the major complex by USF2-specific
antibody appears to be incomplete (Fig. 3A, lanes 4 and 9), this
is not due to inadequate amounts of the antibody, since dilution
of the nuclear extracts did not result in a more complete su-
pershift. Rather, it appears that the remaining E-box binding
complex is likely to be formed by a homodimer of USF1, since
FIG. 2. Functional analysis of the TGF-b2 E-box motif. F9-dif-
ferentiated cells (A), NT2/D1-differentiated cells (B), JAR choriocarci-
noma cells (C), and MCF-7 breast carcinoma cells (D) were transfected
in monolayer with the wild type and mutant TGF-b2 promoter/CAT
plasmids together with the b-galactosidase normalizing plasmids. The
normalizing plasmid was pCH110 in A and B, and pCMVbg in C and D.
Plasmids pb2-77M and pb2-528M contain two point mutations within
the CRE/ATF site of the promoter insert, whereas plasmids pb2-77E
and pb2-528E contain two point mutations within the E-box motif.
Bars, CAT activities of the plasmids relative to the activity of the
pb2-40 construct. CAT activities of pb2-40 in F9-differentiated, NT2/
D1-differentiated, JAR, and MCF-7 cells were 6702, 802, 372, and 1423
cpm, respectively. All experiments in this figure were repeated at least
three times with similar results, using duplicate plates for each plasmid
in A and B, and triplicate plates in C and D. Standard deviations (S.D.)
are shown for these experiments; similar S.D. values were observed in
parallel experiments.
FIG. 3. Gel mobility shift assay between the TGF-b2 E-box
motif and nuclear extracts prepared from F9 EC cells and F9-
differentiated cells. Nuclear extracts were incubated with the 32P-
labeled wild type E-box probe, as described under “Experimental Pro-
cedures.” Competition analysis of DNA-protein complex formation was
performed using a 25-fold molar excess of either the unlabeled wild type
dsODN (WT) or unlabeled mutated dsODN (Mut) in the lanes where
indicated. The arrow indicates the position of the major DNA-protein
complex. 3 mg of USF2-specific antibody was added to lanes 4 and 9 in
A, 3 mg of USF1-specific antibody was added to lanes 4 and 9 in B, and
3 mg of rabbit IgG (negative control) was added to both lanes 5 and 10
of A and B. The experiment was repeated with similar results.
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the USF1-specific antibody caused a nearly complete supershift
of the major E-box binding complexes (Fig. 3B). It should also
be noted, that the supershifted USF1 complex, which is the
faster migrating of the two supershifted complexes in Fig. 3B,
is clearly distinct from the minor complex observed in either F9
EC or F9-differentiated cell nuclear extracts, as demonstrated
by their different mobilities in 8% polyacrylamide gel (data not
shown). Furthermore, the slower migrating supershifted com-
plex formed with USF1-specific antibody co-migrates with the
single supershifted complex formed with USF2-specific anti-
body; thus, these complexes are likely to contain a heterodimer
of USF1 and USF2. Both antibodies caused a decrease in the
binding of the supershifted complexes, which is a frequently
observed phenomenon in gel supershift reactions with mono- or
polyclonal antibodies resulting from the recognition of epitopes
in the DNA binding domain of transcription factors. Overall,
our data suggest that both a heterodimer of USF1/USF2 and a
homodimer of USF1 can bind to this E-box motif in vitro, but
we cannot exclude the possibility that a small amount of USF2
homodimer binds to this site.
We also examined the E-box binding transcription factors
produced by JAR cells and MCF-7 cells, because the E-box
motif is critical for TGF-b2 promoter activity in these cell lines.
Gel mobility shift analyses demonstrated that nuclear extracts
prepared from MCF-7 cells form a very intense DNA-protein
complex with the dsODN probe (Fig. 4A). Although in some
experiments a minor complex appears to migrate just below the
intense complex, the presence of this minor complex was quite
variable, and, thus, does not appear to be significant. Nuclear
extracts from JAR and JEG-3 cells also form an intense band,
which appears to consist of two DNA-protein complexes that
migrate very close to one another (Fig. 4A). The presence of the
two complexes is readily apparent at shorter exposures of the
autoradiogram (data not shown). In addition, both JAR and
JEG-3 nuclear extracts form a second less intense complex that
migrates faster than the main complex. The formation of this
complex, like the one observed with extracts prepared from
MCF-7 cells is variable. Importantly, each of the complexes
observed with nuclear extracts from these three cell lines
bound specifically to the E-box motif, as determined by compe-
tition analyses with the wild type and mutant E-box dsODNs.
It is noteworthy that, although equal amounts of nuclear ex-
tracts (micrograms of protein) were used in the gel mobility
shift assays, JEG-3 cell nuclear extracts appear to contain
significantly less TGF-b2 E-box binding activity than the other
two cell lines (Fig. 4A). Supershift analyses using USF1- and
USF2-specific antibodies demonstrated the presence of both
USF1 and USF2 in the DNA-protein complexes, although sig-
nificantly more USF1 homodimer appears to bind to the E-box
motif in JAR cell nuclear extracts, than in other cell nuclear
extracts tested (Fig. 4B). In this regard, increasing the amount
of the USF1 antibody in other experiments caused a nearly
complete supershift of the DNA-protein complexes bound to the
E-box motif; whereas addition of the USF2 antibody along with
the USF1 antibody did not cause a supershift of the residual
DNA-protein complexes (data not shown). It should also be
noted that, despite the similarity of the USF proteins, the
USF1- and USF2-specific antibodies do not crossreact. This is
demonstrated by the fact that the supershift by USF2-specific
antibody can be blocked only with a peptide fragment derived
from USF2, but not with the blocking peptide derived from
USF1 and vice versa (Fig. 4B). In this regard, the blocking
peptides used in our gel shift studies are the same USF1 or
USF2 peptides used to generate the respective antibodies.
USF Transcription Factors Are Required for TGF-b2 Pro-
moter Activity in Vivo—Despite the binding of USF proteins to
the TGF-b2 E-box motif in vitro, the possibility still remained
that other bHLH-LZ proteins are responsible for the E-box-de-
pendent promoter activity in vivo. Therefore, we employed a
eukaryotic expression plasmid in transient transfection assays
(psvUSF2DB) that expresses a murine USF2 mutant protein,
which lacks the region required for DNA binding (amino acids
228–247) (29). Since specific DNA binding by hetero- or ho-
modimers of USF proteins requires the presence of both pro-
teins’ DNA binding domains (14, 35, 36), the ectopically ex-
pressed mutant USF2 protein would effectively sequester wild
type, endogenous USF1 and USF2 proteins in complexes that
are unable to bind to E-box motifs. Cotransfection of plasmid
psvUSF2DB (expressing mutant USF2) with the pb2-77 pro-
moter/reporter construct reduced promoter activity by approx-
imately 60% in F9-differentiated cells (Fig. 5). This effect ap-
pears to be conveyed specifically through the E-box motif of the
FIG. 4. Gel mobility shift assay between the TGF-b2 E-box
motif and nuclear extracts prepared from JAR and JEG-3 cho-
riocarcinoma cells and MCF-7 breast carcinoma cells. A, nuclear
extracts were incubated with the 32P-labeled wild type E-box probe, as
described under “Experimental Procedures.” Competition analysis of
the DNA-protein complex formation was performed using a 50-fold
molar excess of either the unlabeled wild type dsODN (WT) or unlabeled
mutated dsODN (Mut) in the lanes where indicated. The arrow indi-
cates the position of the major DNA-protein complex(es). B, JAR nu-
clear extract was incubated with the 32P-labeled wild type E-box probe,
as described under “Experimental Procedures.” No extract was added to
lane 1. A 50-fold molar excess of the unlabeled wild type dsODN was
added to lane 3, 1 mg of USF1-specific antibody was added to lanes 4–6,
and 1 mg of USF2-specific antibody was added to lanes 7–9. 10 mg of the
blocking peptide derived from the C terminus of USF2 (PEP2) was
added to lanes 6 and 8, and 10 mg of the blocking peptide derived from
the C terminus of USF1 (PEP1) was added to lanes 5 and 9. The arrow
indicates the position of the major DNA-protein complex(es). The ex-
periment was repeated with similar results.
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promoter, since at the same time no change was observed in the
activities of two different normalizing plasmids, pCH110 or
pCMVbg (Fig. 5, A and B, respectively), which are under the
control of the SV-40 promoter and the CMV promoter, respec-
tively. This observation argues that USF transcription factors
contribute directly to the activity of the TGF-b2 promoter in
F9-differentiated cells. It should be noted that we observed an
average differential of 7-fold between the CAT activity ex-
pressed by the pb2-77 construct and the activity of the pb2-40
construct when transfected into F9-differentiated cells (Fig. 5).
However, in some experiments a smaller differential was ob-
served (Fig. 2A). This variability is likely to result from several
experimental conditions, particularly the extent of differentia-
tion exhibited by the population of F9 EC cells treated with
all-trans-retinoic acid. Nevertheless, the differences observed
between the activities of the unmodified promoter/reporter
gene constructs and their mutated counterparts were consis-
tently larger (approximately 70%) than the standard devia-
tions (,10%) observed between experiments.
DISCUSSION
Our studies identify a critical cis-regulatory element in the
human TGF-b2 gene promoter, which conforms to the consen-
sus binding site of the bHLH-LZ family of transcription factors.
The intact E-box motif is required for TGF-b2 promoter activity
in several cell types, including differentiated cells derived from
murine and human EC cells (F9 EC and NT2/D1 EC, respec-
tively), as well as two choriocarcinoma cell lines (JAR and
JEG-3) and a breast carcinoma cell line (MCF-7). These obser-
vations, together with the fact that the E-box motif is conserved
in a comparable region of the chicken TGF-b2 gene promoter,
suggest that transcription factors binding to the E-box motif, in
conjunction with other factors binding to a similarly conserved
CRE/ATF motif nearby, play an important role in TGF-b2 gene
expression in various systems. In this regard, our gel mobility
shift analyses demonstrated that protein complexes containing
USF1 and USF2 transcription factors are capable of binding to
the TGF-b2 E-box motif in nuclear extracts of all cell types
studied. Moreover, using a dominant-negative mutant of USF2
protein in F9-differentiated cells, we determined that binding
of USF proteins to the E-box motif appears to be critical for the
activity of the TGF-b2 promoter in cells. Interestingly, overex-
pression of USF1 or USF2 in the transfected F9-differentiated
cells induced a general increase in transcription without a
preferential increase in the expression of the TGF-b2 promoter/
reporter gene constructs (data not shown). This suggests that
USF1 and USF2 are not limiting for the expression of the
TGF-b2 gene in F9-differentiated cells.
The data presented here also suggest that TGF-b2 E-box
binding activities, comprised of USF1/USF2 heterodimers and
USF1 homodimers, do not change dramatically upon differen-
tiation of EC cells, similarly to CRE/ATF binding activities (9).
The same observation was made with a murine (F9) and a
human (NT2/D1) EC cell line and their differentiated cells and
with the parietal endoderm-like PYS-2 cell line, which shares
many characteristics with F9-differentiated cells. This was sur-
prising, since the region of the TGF-b2 promoter containing
these cis-regulatory elements is inactive in undifferentiated EC
cells. One possible explanation is that, although DNA-binding
ability of the USF complexes is unaffected by the differentia-
tion status of the cells, they are unable to transactivate in the
undifferentiated cells, perhaps due to their different state of
phosphorylation. In this regard, it has been suggested that the
transactivator domain of USF1 could be converted into an
acidic activation domain upon phosphorylation of the multiple
serine and threonine residues found in this region (37). How-
ever, treatment of F9 EC or F9-differentiated cell nuclear ex-
tracts with calf intestinal alkaline phosphatase does not appear
to affect DNA binding, migration, or the supershift pattern of
the USF complexes (data not shown). Nevertheless, without
thorough analysis of the phosphorylation pattern of USF pro-
teins, it cannot be excluded that TGF-b2 E-box binding USF-
complexes have different transactivator abilities before and
after differentiation of EC cells resulting from differential
phosphorylation. On the other hand, it is also conceivable that
USF complexes may not bind effectively to the TGF-b2 E-box
motif before differentiation of EC cells due to chromatin struc-
ture, or methylation of the binding site. Alternatively, tran-
scription factors that bind to other cis-regulatory elements in
the TGF-b2 gene may interfere with the function of transcrip-
tion factors that bind to the CRE/ATF motif and/or the E-box.
Last, it is important to note that the E-box motif is positioned
between an upstream CRE/ATF site and the downstream
TATA box motif, and, based on the distance between them, all
three motifs are positioned to face the same side of the DNA
helix. This raises the possibility of direct or indirect interac-
tions between the transcription factors binding to these cis-
regulatory elements and the basal transcription machinery,
which are necessary for the formation of an active preinitiation
complex. In this regard, the leucine zipper (LZ) domain of
several members of the bLZ and bHLH-LZ families of tran-
scription factors have been shown to participate in various
interactions with viral proteins or with other transcription
factors (38–42). In addition, USF proteins have been shown to
interact with TFIID binding to the TATA box motif (43). Thus,
it is possible that the activity of the TGF-b2 promoter is regu-
lated through modulation of these essential protein-protein
interactions.
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